Thera-SAbDab

RESLIZUMAB

>   Structural Summary
TherapeuticReslizumab
TargetIL5
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAVSGLSLTSNSVNWIRQAPGKGLEWVGLIWSNGDTDYNSAIKSRFTISRDTSKSTVYLQMNSLRAEDTAVYYCAREYYGYFDYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCLASEGISSYLAWYQQKPGKAPKLLIYGANSLQTGVPSRFSGSGSATDYTLTISSLQPEDFATYYCQQSYKFPNTFGQGTKVEVK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2001
INN Year Recommended2002
Companies InvolvedCelltech R&D, Schering-Plough, Allergy and Asthma Clinical Research, Celltech R&D, Teva Pharmaceutical Industries
Conditions ApprovedAsthma
Conditions ActiveSinusitis, Churg-Strauss syndrome
Conditions DiscontinuedOesophagitis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]